In the Claims

Please cancel claims 1-6 without prejudice.

Please rewrite Claim 7 as follows:

7. (Once amended) An angiogenesis inhibitory composition comprising an angiogenesis inhibiting compound and an anti-inflammatory drug,

wherein the angiogenesis inhibiting compound is selected from the group consisting of:

(1) a compound selected from the formula

A)



B)



or

C)



wherein

R_1 - R_4 are each independently selected from H; OH; =O; straight or branched chain alkanes, alkenes, and alkynes; cyclic alkanes, alkenes, and alkynes; combinations of cyclic and acyclic alkanes, alkenes, and alkynes; alcohol, aldehyde, ketone, carboxylic acid, ester, or ether moieties in combination with acyclic, cyclic, or combination acyclic/cyclic moieties; aza; amino; $-XO_n$ or $-O-XO_n$, where X=N and n=2, X=S and n=2 or 3, or X=P and n=1-3; and halogens;

R_5 - R_8 are each independently selected from



;


or -O-, where Y is absent and R_{10} is =O or Y and R_{10} are each independently the same as R_1;

and R9 is a moiety selected from the group consisting of

D)



E)



F)



G)



and H)



wherein each of R_{11} - R_{17} is independently the same as R_5, and wherein R_{18}, R_{19} and R_{20} are each independently selected from



and n=1 through 4;

(2) a compound selected from the formula



where R_{22} and R_{23} are each independently H, F, Cl, Br, I, CH_3, or $-CH_2-CH_3$;
and R_{24} is H, CH_3, or $-CH_2-CH_3$;
and

(3) a compound selected from the formula



where X is R_6 as defined in (1) above.

Please add the following new claims:

21. (New Claim) The angiogenesis inhibitory composition of Claim 17 wherein the antiinflammatory drug is a steroid.

22. (New Claim) The angiogenesis inhibitory composition of Claim 21 wherein the steroid is selected from the group consisting of cortisol, corticosterone, hydrocortisone, hydrocortisol, cortisone, prednisone, prednisolone, dexamethasone, beclomethasone, betamethasone, mometasone, mometasone furoate, budesonide, triamcinolone acetonide, and fluticasone.

23. (New Claim) An angiogenesis inhibitory composition of Claim 17 wherein the anti-inflammatory drug is a nonsteroidal, anti-inflammatory drug (NSAID).

24. (New Claim) The angiogenesis inhibitory composition of Claim 23 wherein the NSAID is selected from aspirin, acetominophen, ibuprofen, esculetin, phenidone, quercetin, ketoprofen, nordihydroguiaretic acid (NDGA), sulindac, sulindac sulfone, sulindac sulfide, indomethacin, NS-398 (a cyclooxygenase-2 inhibitor), cyclooxygenase-1 inhibitors, methylheptyl imidazole, furegrelate sodium, SKF525AHCL, thromboxane inhibitors, toradol, ecasa, salsalate, diflunisal, mefenamic acid, naproxen, naproxen sodium, floctafenine, meclofenamate, phenylbutazone, oxyphenbutazone, diclofenac, etodolac, fenoprofen, flufenamic acid, flurbiprofen, pirprofen, tolmetin, apazone, fenbufen, nabumetone, oxaprozin, piroxicam, salicylate, and tenoxicam.

25. (New Claim) The angiogenesis inhibitory composition of Claim 23 wherein the NSAID is selected from indomethacin and sulindac.

26. (New Claim) A method for inhibiting angiogenesis in a human or animal comprising administering to the human or animal a composition comprising an angiogenesis inhibiting compound and an anti-inflammatory compound, wherein the angiogenesis inhibiting compound is selected from the group consisting of

(1) a compound selected from the formula

A)



B)



or

C)



wherein

R_1 - R_4 are each independently selected from H; OH; =O; straight or branched chain alkanes, alkenes, and alkynes; cyclic alkanes, alkenes, and alkynes; combinations of cyclic and acyclic alkanes, alkenes, and alkynes; alcohol, aldehyde, ketone, carboxylic acid, ester, or ether moieties in combination with acyclic, cyclic, or combination acyclic/cyclic moieties; aza; amino; $-XO_n$ or $-O-XO_n$, where X=N and n=2, X=S and n=2 or 3, or X=P and n=1-3; and halogens;

R_5 - R_8 are each independently selected from



or -O-, where Y is absent and R_{10} is =O or Y and R_{10} are each independently the same as R_1;

and R_9 is a moiety selected from the group consisting of

D)



E)



F)



G)



and H)



wherein each of R_{11} - R_{17} is independently the same as R_5, and wherein R_{18}, R_{19} and R_{20} are each independently selected from

H, CH_3, 

and n=1 through 4;

(2) a compound selected from the formula



where R_{22} and R_{23} are each independently H, F, Cl, Br, I, CH_3, or $-CH_2-CH_3$;
and R_{24} is H, CH_3, or $-CH_2-CH_3$;
and

(3) a compound selected from the formula



where X is R_6 as defined in (1) above; and

27. (New Claim) A method for treating an angiogenesis dependent disease in a human or animal having such a disease comprising administering to the human or animal a composition comprising an angiogenesis inhibiting compound and an antiinflammatory compound

wherein the angiogenesis inhibiting compound is selected from the group consisting of

(1) a compound selected from the formula

A)



B)



or

C)



wherein

R_1 - R_4 are each independently selected from H; OH; =O; straight or branched chain alkanes, alkenes, and alkynes; cyclic alkanes, alkenes, and alkynes; combinations of cyclic and acyclic alkanes, alkenes, and alkynes; alcohol, aldehyde, ketone, carboxylic acid, ester, or ether moieties in combination with acyclic, cyclic, or combination acyclic/cyclic moieties; aza; amino; $-XO_n$ or $-O-XO_n$, where X=N and n=2, X=S and n=2 or 3, or X=P and n=1-3; and halogens;

R_5 - R_8 are each independently selected from



or -O-, where Y is absent and R_{10} is =O or Y and R_{10} are each independently the same as R_1;

and R_9 is a moiety selected from the group consisting of

D)



E)



F)



G)



and H)



wherein each of R_{11} - R_{17} is independently the same as R_5, and wherein R_{18}, R_{19} and R_{20} are each independently selected from



and n=1 through 4;

(2) a compound selected from the formula



where R_{22} and R_{23} are each independently H, F, Cl, Br, I, CH_3, or $-CH_2-CH_3$;
and R_{24} is H, CH_3, or $-CH_2-CH_3$;
and

(3) a compound selected from the formula



where X is R_6 as defined in (1) above.

28. (New Claim) The method of Claim 27 wherein the angiogenesis dependent disease is selected from macular degeneration, diabetic retinopathy, neovascular glaucoma, retrolental fibroplasias, proliferative vitreoretinopathy, solid tumors, blood-borne tumors, leukemia, hemangioma, psoriasis, Kaposi's sarcoma, Crohn's disease, ulcerative colitis, cancer, retinopathy of prematurity, corneal graft rejection, epidemic keratoconjunctivitis, Vitamin A deficiency, contact lens overwear, atopic keratitis, superior limbic keratitis, pterygium keratitis sicca, sjogren's syndrome, acne rosacea, phylectenulosis, syphilis, *Mycobacteria* infections, lipid degeneration, chemical burns, bacterial ulcers, fungal ulcers, *Herpes simplex* infections, *Herpes zoster* infections, Mooren's ulcer, Terrien's marginal degeneration, marginal keratolysis, trauma, rheumatoid arthritis systemic lupus, polyarteritis, Wegener's sarcoidosis, scleritis, Stevens-Johnson disease, radial keratotomy, corneal graft rejection, sickle cell anemia, pseudoxanthoma elasticum, pemphigoid, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis, chronic vitritis, Lyme's disease, systemic lupus erythematosis, Eales' disease, Behcet's disease, presumed ocular histoplasmosis, Best's disease, myopia, optic pits, Stargardt's disease, pars planitis, chronic retinal detachment, hyperviscosity syndromes, toxoplasmosis, post-laser complications, and rubeosis.

29. (New Claim) The angiogenesis inhibitory composition of Claim 7 wherein the dosage of the angiogenesis inhibiting compound is between about 0.1 to about 300 mg/kg/day.

30. (New Claim) The angiogenesis inhibitory composition of Claim 7 wherein the dosage of the angiogenesis inhibiting compound is between about 0.5 to about 50 mg/kg/day.

31. (New Claim) The angiogenesis inhibitory composition of Claim 17 wherein the dosage of the angiogenesis inhibiting compound is between about 1 to about 10 mg/kg/day.

32. (New Claim) The method of Claim 24 wherein the composition comprises a formulation suitable for oral, rectal, ophthalmic, nasal, topical, vaginal, or parenteral administration.

33. (New Claim) The method of Claim 22 wherein the composition comprises a formulation suitable for oral, rectal, ophthalmic, nasal, topical, vaginal, or parenteral administration.

34. (New Claim) The method of Claim 25 wherein the dosage of the angiogenesis inhibiting compound is between about 0.1 mg/kg/day to about 300 mg/kg/day.

35. (New Claim) The method of Claim 26 wherein the dosage of the angiogenesis inhibiting compound is between about 0.5 mg/kg/day to about 50 mg/kg/day.

36. (New Claim) The method of Claim 27 wherein the dosage of the angiogenesis inhibiting compound is between about 1 mg/kg/day to about 10 mg/kg/day.

37. (New Claim) The method of Claim 31 wherein the dosage of the angiogenesis inhibiting compound is between about 0.1 mg/kg/day to about 300 mg/kg/day.

38. (New Claim) The method of Claim 32 wherein the dosage of the angiogenesis inhibiting compound is between about 0.5 mg/kg/day to about 50 mg/kg/day.

39. (New Claim) The method of Claim 33 wherein the dosage of the angiogenesis inhibiting compound is between about 1 mg/kg/day to about 10 mg/kg/day.

40. (New Claim) An angiogenesis inhibitory composition comprising an angiogenesis inhibiting compound and an anti-inflammatory drug,

wherein the angiogenesis inhibiting compound has the formula



41. (New Claim) The angiogenesis inhibitory composition of Claim 40 wherein the antiinflammatory drug is a steroid.

42. (New Claim) The angiogenesis inhibitory composition of Claim 41 wherein the steroid is selected from the group consisting of cortisol, corticosterone, hydrocortisone, hydrocortisol, cortisone, prednisone, prednisolone, dexamethasone, beclomethasone, betamethasone, mometasone, mometasone furoate, budesonide, triamcinolone acetonide, and fluticasone.

43. (New Claim) An angiogenesis inhibitory composition of Claim 41 wherein the anti-inflammatory drug is a nonsteroidal, anti-inflammatory drug (NSAID).

44. (New Claim) The angiogenesis inhibitory composition of Claim 43 wherein the NSAID is selected from aspirin, acetominophen, ibuprofen, esculetin, phenidone, quercetin, ketoprofen, nordihydroguiaretic acid (NDGA), sulindac, sulindac sulfone, sulindac sulfide, indomethacin, NS-398 (a cyclooxygenase-2 inhibitor), cyclooxygenase-1 inhibitors, methylheptyl imidazole, furegrelate sodium, SKF525AHCL, thromboxane inhibitors, toradol, ecasa, salsalate, diflunisal, mefenamic acid, naproxen, naproxen sodium, floctafenine, meclofenamate, phenylbutazone, oxyphenbutazone, diclofenac, etodolac, fenoprofen, flufenamic acid, flurbiprofen, pirprofen, tolmetin, apazone, fenbufen, nabumetone, oxaprozin, piroxicam, salicylate, and tenoxicam.